Literature DB >> 21628406

Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells.

Su Mi Choi1, Hua Liu, Pooja Chaudhari, Yonghak Kim, Linzhao Cheng, Jian Feng, Saul Sharkis, Zhaohui Ye, Yoon-Young Jang.   

Abstract

EBV-immortalized B lymphocyte cell lines have been widely banked for studying a variety of diseases, including rare genetic disorders. These cell lines represent an important resource for disease modeling with the induced pluripotent stem cell (iPSC) technology. Here we report the generation of iPSCs from EBV-immortalized B-cell lines derived from multiple inherited disease patients via a nonviral method. The reprogramming method for the EBV cell lines involves a distinct protocol compared with that of patient fibroblasts. The B-cell line-derived iPSCs expressed pluripotency markers, retained the inherited mutation and the parental V(D)J rearrangement profile, and differentiated into all 3 germ layer cell types. There was no integration of the reprogramming-related transgenes or the EBV-associated genes in these iPSCs. The ability to reprogram the widely banked patient B-cell lines will offer an unprecedented opportunity to generate human disease models and provide novel drug therapies.

Entities:  

Mesh:

Year:  2011        PMID: 21628406      PMCID: PMC3158714          DOI: 10.1182/blood-2011-03-340620

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells.

Authors:  Tomohisa Seki; Shinsuke Yuasa; Mayumi Oda; Toru Egashira; Kojiro Yae; Dai Kusumoto; Hikari Nakata; Shugo Tohyama; Hisayuki Hashimoto; Masaki Kodaira; Yohei Okada; Hiroyuki Seimiya; Noemi Fusaki; Mamoru Hasegawa; Keiichi Fukuda
Journal:  Cell Stem Cell       Date:  2010-07-02       Impact factor: 24.633

2.  Simple generation of human induced pluripotent stem cells using poly-beta-amino esters as the non-viral gene delivery system.

Authors:  Núria Montserrat; Elena Garreta; Federico González; Jordán Gutiérrez; Cristina Eguizábal; Víctor Ramos; Salvador Borrós; Juan Carlos Izpisua Belmonte
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

3.  Reprogramming of human peripheral blood cells to induced pluripotent stem cells.

Authors:  Judith Staerk; Meelad M Dawlaty; Qing Gao; Dorothea Maetzel; Jacob Hanna; Cesar A Sommer; Gustavo Mostoslavsky; Rudolf Jaenisch
Journal:  Cell Stem Cell       Date:  2010-07-02       Impact factor: 24.633

4.  Reprogramming of T cells from human peripheral blood.

Authors:  Yuin-Han Loh; Odelya Hartung; Hu Li; Chunguang Guo; Julie M Sahalie; Philip D Manos; Achia Urbach; Garrett C Heffner; Marica Grskovic; Francois Vigneault; M William Lensch; In-Hyun Park; Suneet Agarwal; George M Church; James J Collins; Stefan Irion; George Q Daley
Journal:  Cell Stem Cell       Date:  2010-07-02       Impact factor: 24.633

5.  In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins.

Authors:  Hua Liu; Yonghak Kim; Saul Sharkis; Luigi Marchionni; Yoon-Young Jang
Journal:  Sci Transl Med       Date:  2011-05-11       Impact factor: 17.956

6.  Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells.

Authors:  Kejin Hu; Junying Yu; Kran Suknuntha; Shulan Tian; Karen Montgomery; Kyung-Dal Choi; Ron Stewart; James A Thomson; Igor I Slukvin
Journal:  Blood       Date:  2011-02-04       Impact factor: 22.113

7.  Human induced pluripotent stem cells free of vector and transgene sequences.

Authors:  Junying Yu; Kejin Hu; Kim Smuga-Otto; Shulan Tian; Ron Stewart; Igor I Slukvin; James A Thomson
Journal:  Science       Date:  2009-03-26       Impact factor: 47.728

8.  Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.

Authors:  Luigi Warren; Philip D Manos; Tim Ahfeldt; Yuin-Han Loh; Hu Li; Frank Lau; Wataru Ebina; Pankaj K Mandal; Zachary D Smith; Alexander Meissner; George Q Daley; Andrew S Brack; James J Collins; Chad Cowan; Thorsten M Schlaeger; Derrick J Rossi
Journal:  Cell Stem Cell       Date:  2010-09-30       Impact factor: 24.633

Review 9.  Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease.

Authors:  Yong Soon Chun; Pooja Chaudhari; Yoon-Young Jang
Journal:  Int J Biol Sci       Date:  2010-12-14       Impact factor: 6.580

10.  Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures.

Authors:  Bin-Kuan Chou; Prashant Mali; Xiaosong Huang; Zhaohui Ye; Sarah N Dowey; Linda Ms Resar; Chunlin Zou; Y Alex Zhang; Jay Tong; Linzhao Cheng
Journal:  Cell Res       Date:  2011-01-18       Impact factor: 25.617

View more
  51 in total

Review 1.  Induced pluripotent stem cells--opportunities for disease modelling and drug discovery.

Authors:  Marica Grskovic; Ashkan Javaherian; Berta Strulovici; George Q Daley
Journal:  Nat Rev Drug Discov       Date:  2011-11-11       Impact factor: 84.694

2.  Reprogramming human B cells into induced pluripotent stem cells and its enhancement by C/EBPα.

Authors:  C Bueno; J L Sardina; B Di Stefano; D Romero-Moya; A Muñoz-López; L Ariza; M C Chillón; A Balanzategui; J Castaño; A Herreros; M F Fraga; A Fernández; I Granada; O Quintana-Bustamante; J C Segovia; K Nishimura; M Ohtaka; M Nakanishi; T Graf; P Menendez
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

Review 3.  Expression kinetics of hepatic progenitor markers in cellular models of human liver development recapitulating hepatocyte and biliary cell fate commitment.

Authors:  Pooja Chaudhari; Lipeng Tian; Abhijeet Deshmukh; Yoon-Young Jang
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-06

4.  Liver engraftment potential of hepatic cells derived from patient-specific induced pluripotent stem cells.

Authors:  Su Mi Choi; Yonghak Kim; Hua Liu; Pooja Chaudhari; Zhaohui Ye; Yoon-Young Jang
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

Review 5.  Human-relevant preclinical in vitro models for studying hepatobiliary development and liver diseases using induced pluripotent stem cells.

Authors:  Pooja Chaudhari; Lipeng Tian; Zhaohui Ye; Yoon-Young Jang
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-26

Review 6.  Modeling heterogeneous patients with a clinical diagnosis of schizophrenia with induced pluripotent stem cells.

Authors:  Kristen J Brennand; Melissa A Landek-Salgado; Akira Sawa
Journal:  Biol Psychiatry       Date:  2013-11-15       Impact factor: 13.382

7.  IFNL3 genotype is associated with differential induction of IFNL3 in primary human hepatocytes.

Authors:  Fuat Kurbanov; Yonghak Kim; Rachel Latanich; Pooja Chaudhari; Ramy El-Diwany; Matt Knabel; Abraham J Kandathil; Andrew Cameron; Andrea Cox; Yoon-Young Jang; David L Thomas; Ashwin Balagopal
Journal:  Antivir Ther       Date:  2015-06-25

8.  Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells.

Authors:  Su Mi Choi; Yonghak Kim; Joong Sup Shim; Joon Tae Park; Rui-Hong Wang; Steven D Leach; Jun O Liu; Chuxia Deng; Zhaohui Ye; Yoon-Young Jang
Journal:  Hepatology       Date:  2013-06       Impact factor: 17.425

9.  Efficient and Controlled Generation of 2D and 3D Bile Duct Tissue from Human Pluripotent Stem Cell-Derived Spheroids.

Authors:  Lipeng Tian; Abhijeet Deshmukh; Zhaohui Ye; Yoon-Young Jang
Journal:  Stem Cell Rev Rep       Date:  2016-08       Impact factor: 5.739

10.  C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells.

Authors:  Rustam Esanov; Kinsley C Belle; Marka van Blitterswijk; Veronique V Belzil; Rosa Rademakers; Dennis W Dickson; Leonard Petrucelli; Kevin B Boylan; Derek M Dykxhoorn; Joanne Wuu; Michael Benatar; Claes Wahlestedt; Zane Zeier
Journal:  Exp Neurol       Date:  2015-12-31       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.